UB Paderborn / Katalog / Suche / in CDI

Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor

Journal of thrombosis and haemostasis, 2010-06, Vol.8 (6), p.1302-1312

2010

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the profibrinolytic properties of a bispecific antibody‐based inhibitor against human and mouse thrombin‐activatable fibrinolysis inhibitor and plasminogen activator inhibitor‐1

Journal of thrombosis and haemostasis, 2013-11, Vol.11 (11), p.2069-2071

2013

Link zum Volltext

Verfügbarkeit prüfen

Plasmin and the thrombin–thrombomodulin complex both contribute to thrombin‐activatable fibrinolysis inhibitor activation in whole blood model thrombi

Journal of thrombosis and haemostasis, 2013-01, Vol.11 (1), p.190-192

2013

Link zum Volltext

Verfügbarkeit prüfen

Systemic inhibition and liver‐specific over‐expression of PAI‐1 failed to improve survival in all‐inclusive populations or homogenous cohorts of CLP mice

Journal of thrombosis and haemostasis, 2014-06, Vol.12 (6), p.958-969

2014

Link zum Volltext

Verfügbarkeit prüfen

The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study

Journal of thrombosis and haemostasis, 2009-06, Vol.7 (6), p.919-927

2009

Link zum Volltext

Verfügbarkeit prüfen

Increased zymogen activity of thrombin‐activatable fibrinolysis inhibitor prolongs clot lysis

Journal of thrombosis and haemostasis, 2012-06, Vol.10 (6), p.1091-1099

2012

Link zum Volltext

Verfügbarkeit prüfen

Convalescent plasma levels of TAFI activation peptide predict death and recurrent vascular events in ischemic stroke survivors

Journal of thrombosis and haemostasis, 2012-04, Vol.10 (4), p.725-727

2012

Link zum Volltext

Verfügbarkeit prüfen

Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor‐1 by a heterodimer diabody

Journal of thrombosis and haemostasis, 2008-11, Vol.6 (11), p.1884-1891

2008

Link zum Volltext

Verfügbarkeit prüfen

O-31: Biologicals and biosimilars: Is similar the same?

Journal of Crohn's and colitis, 2014-09, Vol.8, p.S427-S427

Declerck, P.J.

2014

Link zum Volltext

Verfügbarkeit prüfen

Generation of a stable thrombin‐activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation

Journal of thrombosis and haemostasis, 2015-06, Vol.13 (6), p.1084-1089

2015

Link zum Volltext

Verfügbarkeit prüfen

Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice

Journal of thrombosis and haemostasis, 2017-12, Vol.15 (12), p.2432-2442

2017

Link zum Volltext

Verfügbarkeit prüfen

Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin‐activatable fibrinolysis inhibitor activation and activated thrombin‐activatable fibrinolysis inhibitor activity

Journal of thrombosis and haemostasis, 2016-08, Vol.14 (8), p.1629-1638

2016

Link zum Volltext

Verfügbarkeit prüfen

Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin‐activatable fibrinolysis inhibitor but not the anti‐inflammatory activity on osteopontin and C5a

Journal of thrombosis and haemostasis, 2013-12, Vol.11 (12), p.2137-2147

2013

Link zum Volltext

Verfügbarkeit prüfen

Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator

The Journal of biological chemistry, 1992-06, Vol.267 (17), p.11693-11696

1992

Link zum Volltext

Verfügbarkeit prüfen

The hyperfibrinolytic state of mice with combined thrombin‐activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor‐1 gene deficiency is critically dependent on TAFI deficiency

Journal of thrombosis and haemostasis, 2012-12, Vol.10 (12), p.2555-2562

2012

Link zum Volltext

Verfügbarkeit prüfen

Identification of a novel, nanobody‐induced, mechanism of TAFI inactivation and its in vivo application

Journal of thrombosis and haemostasis, 2014-02, Vol.12 (2), p.229-236

2014

Link zum Volltext

Verfügbarkeit prüfen

TAFIa inhibiting nanobodies as profibrinolytic tools and discovery of a new TAFIa conformation

Journal of thrombosis and haemostasis, 2011-11, Vol.9 (11), p.2268-2277

2011

Link zum Volltext

Verfügbarkeit prüfen

Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop

The Journal of biological chemistry, 1994-07, Vol.269 (30), p.19559-19564

1994

Link zum Volltext

Verfügbarkeit prüfen

Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study

Journal of thrombosis and haemostasis, 2009-01, Vol.7 (1), p.49-57

2009

Link zum Volltext

Verfügbarkeit prüfen

Thrombin activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children

Journal of thrombosis and haemostasis, 2008-02, Vol.6 (2), p.268-276

2008

Link zum Volltext

Verfügbarkeit prüfen

Discovery of novel mechanisms and molecular targets for the inhibition of activated thrombin activatable fibrinolysis inhibitor

Journal of thrombosis and haemostasis, 2008-11, Vol.6 (11), p.1892-1899

2008

Link zum Volltext

Verfügbarkeit prüfen

High quality structure of cleaved PAI-1-stab

Journal of structural biology, 2009-02, Vol.165 (2), p.126-132

2009

Link zum Volltext

Verfügbarkeit prüfen

Modulation of TAFI function through different pathways – implications for the development of TAFI inhibitors

Journal of thrombosis and haemostasis, 2005-12, Vol.3 (12), p.2745-2753

2005

Link zum Volltext

Verfügbarkeit prüfen

Announcing a TAFIa mutant with a 180‐fold increased half‐life and concomitantly a strongly increased antifibrinolytic potential

Journal of thrombosis and haemostasis, 2007-02, Vol.5 (2), p.418-420

2007

Link zum Volltext

Verfügbarkeit prüfen

Reactive site‐dependent phenotypic alterations in plasminogen activator inhibitor‐1 transgenic mice

Journal of thrombosis and haemostasis, 2007-07, Vol.5 (7), p.1500-1508

2007

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor

Evaluation of the profibrinolytic properties of a bispecific antibody‐based inhibitor against human and mouse thrombin‐activatable fibrinolysis inhibitor and plasminogen activator inhibitor‐1

Plasmin and the thrombin–thrombomodulin complex both contribute to thrombin‐activatable fibrinolysis inhibitor activation in whole blood model thrombi

Systemic inhibition and liver‐specific over‐expression of PAI‐1 failed to improve survival in all‐inclusive populations or homogenous cohorts of CLP mice

The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study

Increased zymogen activity of thrombin‐activatable fibrinolysis inhibitor prolongs clot lysis

Convalescent plasma levels of TAFI activation peptide predict death and recurrent vascular events in ischemic stroke survivors

Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor‐1 by a heterodimer diabody

O-31: Biologicals and biosimilars: Is similar the same?

Generation of a stable thrombin‐activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation

Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice

Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin‐activatable fibrinolysis inhibitor activation and activated thrombin‐activatable fibrinolysis inhibitor activity

Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin‐activatable fibrinolysis inhibitor but not the anti‐inflammatory activity on osteopontin and C5a

Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator

The hyperfibrinolytic state of mice with combined thrombin‐activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor‐1 gene deficiency is critically dependent on TAFI deficiency

Identification of a novel, nanobody‐induced, mechanism of TAFI inactivation and its in vivo application

TAFIa inhibiting nanobodies as profibrinolytic tools and discovery of a new TAFIa conformation

Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop

Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study

Thrombin activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children

Discovery of novel mechanisms and molecular targets for the inhibition of activated thrombin activatable fibrinolysis inhibitor

High quality structure of cleaved PAI-1-stab

Modulation of TAFI function through different pathways – implications for the development of TAFI inhibitors

Announcing a TAFIa mutant with a 180‐fold increased half‐life and concomitantly a strongly increased antifibrinolytic potential

Reactive site‐dependent phenotypic alterations in plasminogen activator inhibitor‐1 transgenic mice

Suchergebnisse filtern